⦁ Using VHH antibodies as building blocks, we are developing novel, next-generation bispecific and multispecific antibody drugs to improve clinical outcomes for cancer patients with resistance and/or unmet medical needs.
⦁ We focus on developing novel bispecific antibody-drug conjugates and T-cell engagers to address the heterogeneity of solid tumors, the leading cause of tumor relapse when treated with monospecific tumor-associated antigen targeting therapies that only kill one subpopulation of cancer cells.
